Cogent Biosciences, Inc. (COGT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Cogent Biosciences, Inc. in 2026. The next earnings report is expected on November 10, 2026.
Cogent Biosciences beat consensus estimates in its latest earnings report, with EPS of -$0.5448 versus an estimate of -$0.5508, and revenue met expectations at $0. In the prior quarter EPS also came in ahead of expectations while revenue met forecasts.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
